Russell Luisa M, Liu Christina H, Grodzinski Piotr
Nanodelivery Systems and Devices Branch, Cancer Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Nanodelivery Systems and Devices Branch, Cancer Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Biomaterials. 2020 Jun;242:119926. doi: 10.1016/j.biomaterials.2020.119926. Epub 2020 Feb 29.
Nanomedicines have been developing very rapidly and have started to play a significant role in several cancer therapeutic modalities. Early on, the nanomedicine field focused on optimizing pharmacokinetics, toxicity, and/or biodistribution of an agent through nanoparticle formulation. In other cases, where materials science is employed more decisively, nanomedicine can include the creation of new agents that take advantage of nanoscale materials properties to enhance treatment efficacy through unique mode of action, molecular targeting, or controlled drug release. Both current and future nanomedicines will seek to contribute to the therapeutic and diagnostic landscape through creative leveraging of mechanical, electrical, optical, magnetic, and biological nanomaterial properties. In this work, we discuss how by modulating these material properties, one can design more diverse and more effective cancer interventions. We focus on six areas in cancer management, including in vitro diagnostics, clinical imaging, theranostics, combination therapy, immunotherapy, and gene therapy.
纳米药物发展非常迅速，并已开始在多种癌症治疗方式中发挥重要作用。早期，纳米药物领域专注于通过纳米颗粒制剂优化药物的药代动力学、毒性和/或生物分布。在其他更果断采用材料科学的情况下，纳米药物可包括开发新药物，这些药物利用纳米级材料特性，通过独特的作用方式、分子靶向或控释来提高治疗效果。当前和未来的纳米药物都将通过创造性地利用机械、电学、光学、磁性和生物纳米材料特性，为治疗和诊断领域做出贡献。在这项工作中，我们讨论了如何通过调节这些材料特性来设计更多样化、更有效的癌症干预措施。我们专注于癌症管理的六个领域，包括体外诊断、临床成像、诊疗一体化、联合治疗、免疫治疗和基因治疗。
